Roles
- Professor of Clinical Ophthalmology
- Secondary Appointment in the Department of Dermatology
-
Biography
Dr. Lee earned her medical degree from Tulane University. She holds a Bachelor of Arts degree from the University of California at Santa Barbara and a Master of Science degree from Georgetown University. She completed her residency and internship at Tulane University, and a fellowship in oculoplastic and reconstructive surgery at Bascom Palmer Eye Institute.
Dr. Lee treats a broad spectrum of oculoplastic disorders, including periocular tumors, infection and inflammation, facial trauma, tearing, and eyelid malpositions. In addition, Dr. Lee provides aesthetic services, including ptosis surgery; blepharoplasty; brow and forehead lifts; botulinum toxin injections, dermal fillers, and photorejuvenation.
Dr. Lee dedicates time to teaching and is co-director of UM Cosmetic Medicine. Her research interests include eyelid reconstruction, aging of the eyelid skin, and aesthetic lasers. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Honors & Awards
-
Teaching Interests
Oculofacial Plastic & Reconstructive Surgery -
Research Interests
Aesthetic applications of oculoplastic surgery
Eyelid Reconstruction -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Professional Activities
Clinical Trials
Viewing 0 of 4 clinical trials.
-
Our study aims to investigate if Upneeq (oxymetazoline hydrochloride 0.1%) eye drops will improve patient eyelid position, eye redness, and patient-reported eye appearance.
- Principal Investigator: Wendy Lee
- Study Phase: Phase IV
- Enrollment Status: Closed
-
To evaluate topical use of botulinum toxin on eyelid hight, ocular surface and tearing
- Principal Investigator: Wendy Lee
- Study Phase: Approved Drug/Off-Label use
- Enrollment Status: Closed
-
A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN 001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) and Subjects With Thyroid Eye Disease (TED)
- Principal Investigator: Wendy Lee
- Study Phase: Phase 2/Phase 3
- Enrollment Status: Closed
-
The purpose of this phase 3 clinical study is to determine the safety, tolerability, and efficacy of VRDN-001 when given as 5 infusions of 10 mg/kg compared to placebo in participants with chronic thyroid eye disease (TED). Approximately 159 participants are expected to take part across approximately 55 study clinics based in Australia, Canada, Israel, Turkey, European Union, United Kingdom, and USA. Approximately 106 participants will receive treatment with VRDN-001 and 53 participants will receive treatment with a placebo.
- Principal Investigator: Wendy Lee
- Study Phase: TBD
- Enrollment Status: Closed
